Pharma major Dr Reddy’s Laboratories Ltd has launched Bivalirudin for injection.
It is the therapeutic equivalent generic version of Angiomax (Bivalirudin) for injection, approved by the US Food and Drug Administration (USFDA). Angiomax is a registered trademark of The Medicines Company.
The Angiomax brand and generic had US sales of approximately $198 million for the most recent 12 months ending March 2017, according to IMS Health,
Hyderabad-based Dr Reddy’s Bivalirudin injection is available in packages of 10 single-dose vials, according to a release.